Recent research: Asia Pacific Vaccines Market highly favorable to the growth rate by 2027

According to The Insight Partners market research study titled ‘Vaccines Market - Global Analysis and Forecasts by Technology, Disease Indication, Route of Administration, and Patient Type. The global vaccines market is expected to reach US$ 64,538.4 Mn in 2027 from US$ 36,998.8 in 2018. The market is estimated to grow with a CAGR of 6.5% from 2019-2027. The report highlights the trends prevalent in the global vaccines market and the factors driving the market along with those that act as deterrents to its growth.

The vaccines market by technology is segmented into Recombinant vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, and Toxoid Vaccines. In 2018, the conjugate vaccines segment held a largest market share of 65.1% of the vaccines market, By Technology. This segment is also expected to dominate the market in 2027 as they are the most effective forms of immunization, used to prevent diseases in both infants and adults. Moreover, the similar segment is anticipated to also witness the fastest growth rate of 6.7% during the forecast period, 2019 to 2027 owing to the increasing demand for drugs to treat the disease.

Driving factors such as, growing focus on immunization programs, increasing support for vaccine development, rising prevalence of infectious diseases. However, the complexity and cost of vaccine manufacturing and soaring costs of vaccines are likely to pose a negative impact on the market growth. On the other hand, robust pipeline of vaccines is likely to have a positive impact on the growth of the global vaccines market in the coming years.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.theinsightpartners.com/sample/TIPRE00005749/

Some of the prominent players operating in vaccines market are PFIZER INC, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi, Johnson & Johnson Services, Inc, Panacea Biotec Limited, Astellas Pharma Inc., NOVAVAX, INC., VBI Vaccines Inc, and Bavarian Nordic. The market players are focused towards bringing new and innovative products and services to sustain their position in the market. For instance, in December, 2018, The European Commission has granted marketing authorization for Dengvaxia, Sanofi’s dengue vaccine. The marketing authorization follows the October 18, 2018, recommendation by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to approve use of the dengue vaccine in European endemic areas. The developments performed by the companies are helping the market to grow in the coming years.

ASIA PACIFIC VACCINES– MARKET SEGMENTATION

By Technology

• Recombinant vaccines
• Conjugate Vaccines
• Live Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines

ASIA PACIFIC VACCINES – MARKET SEGMENTATION

By Disease Indication

• DTP (diphtheria, tetanus, and pertussis)
• Influenza
• Hepatitis
• Other Diseases

ASIA PACIFIC VACCINES – MARKET SEGMENTATION

By Rout of Administration

• Oral
• Injectable
• Other

ASIA PACIFIC VACCINES – MARKET SEGMENTATION

By Patient Type

• Adults
• Pediatric

By Country

• China
• Japan
• India
• Australia
• South Korea

Companies Mentioned

• PFIZER INC
• GlaxoSmithKline plc.
• Merck & Co., Inc.
• Sanofi
• Johnson & Johnson Services, Inc
• Panacea Biotec Limited
• Astellas Pharma Inc.
• NOVAVAX, INC.
• VBI Vaccines Inc
• Bavarian Nordic

Purchase a copy of this research report @ https://www.theinsightpartners.com/buy/TIPRE00005749/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com